公开(公告)号：US4720454A

公开(公告)日：1988-01-19

申请号：US601650

申请日：1984-04-18

申请人： Perrin C. White ,  Bo Dupont ,  Maria I. New

发明人： Perrin C. White ,  Bo Dupont ,  Maria I. New

IPC分类号： C12N9/02 ,  C12Q1/68 ,  C12N15/00

CPC分类号： C12N9/0087 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/172

摘要： A cDNA clone is isolated encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation (P-450.sub.C21). This plasmid pC21a contains an insert of 520 base pairs. It hybridizes with mRNA encoding P-450.sub.C21. The peptide encoded by the insert is highly homologous to two peptides isolated from porcine P-450.sub.C21 and shows limited homology to the P-450 induced by phenobarbital in rat liver. This probe and its human equivalents can be used to screen in utero i.e. pre-natal as well as post-natal patients for adrenal hyperplasia since it reacts well with human DNA as shown. These probes can also be useful for an industrial fermentation process to produce cortisone in quantity.

摘要翻译： 分离cDNA克隆，其编码对类固醇21-羟基化（P-450C21）特异性的牛肾上腺细胞色素P-450。 该质粒pC21a含有520个碱基对的插入片段。 它与编码P-450C21的mRNA杂交。 由插入片段编码的肽与从猪P-450C21分离的两种肽高度同源，并且与大鼠肝脏中苯巴比妥诱导的P-450显示有限的同源性。 该探针及其人类等同物可用于筛选子宫内，即出生前以及出生后患者的肾上腺增生，因为如图所示，它与人类DNA发生反应良好。 这些探针也可用于工业发酵过程以量产生可的松。

公开(公告)号：US20240350547A1

公开(公告)日：2024-10-24

申请号：US18749852

申请日：2024-06-21

申请人： Memorial Sloan-Kettering Cancer Center ,  Sloan-Kettering Institute for Cancer Research ,  Memorial Hospital for Cancer and Allied Diseases

发明人： Michel Sadelain ,  Karlo Perica

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464438 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70575

摘要： The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor. It relates to cells comprising: an antigen-recognizing receptor (e.g., a chimeric antigen receptor, a TCR, or a TCR like fusion molecule), a Fas ligand polypeptide (FasL), and a gene disruption of a Fas locus. The gene disruption of the Fas locus can improve the activity and/or efficiency of the cells. The presently disclosed cells, compositions, and methods can be used in allogeneic settings.

公开(公告)号：US20240336698A1

公开(公告)日：2024-10-10

申请号：US18283547

申请日：2022-03-22

申请人： Memorial Sloan Kettering Cancer Center ,  Sloan-Kettering Institute For Cancer Research ,  Memorial Hospital For Cancer and Allied Diseases ,  Stichting VUmc

发明人： Maria Themeli ,  Michel Sadelain ,  Maria Sjöstrand ,  Afroditi Katsarou

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725

CPC分类号： C07K16/2896 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464417 ,  A61K39/464426 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/2878 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/28 ,  C07K2317/24 ,  C07K2317/622

摘要： The presently disclosed subject matter provides uses of a chimeric costimulatory receptor (CCR) targeting CD38, and cells comprising a CD38 CCR and an antigen-recognizing receptor, and uses of such cells.

公开(公告)号：US20240321396A1

公开(公告)日：2024-09-26

申请号：US18575530

申请日：2022-06-29

申请人： Memorial Sloan-Kettering Cancer Center ,  Memorial Hospital for Cancer and Allied Diseases ,  Sloan-Kettering Institute for Cancer Research

发明人： Jonathan Chee Ming Wan ,  Luis A. Diaz,, JR.

IPC分类号： G16B30/00 ,  C12Q1/6874 ,  C12Q1/6883 ,  C12Q1/6886 ,  G16B40/20

CPC分类号： G16B30/00 ,  C12Q1/6874 ,  C12Q1/6883 ,  C12Q1/6886 ,  G16B40/20

摘要： The present technology relates to methods, computing devices, and systems for identifying somatic mutational signatures (e.g., cancer, aging) from whole genome sequencing (e.g., low coverage WGS) of cell-free DNA (cfDNA) obtained from subjects. Machine learning techniques may be applied to cfDNA mutational profiles, permitting accurate discrimination between cancer patients and healthy individuals or discrimination between different cancer types.

公开(公告)号：US20240282410A1

公开(公告)日：2024-08-22

申请号：US18571085

申请日：2022-06-17

申请人： Memorial Sloan-Kettering Cancer Center ,  Memorial Hospital for Cancer and Allied Diseases ,  Sloan-Kettering Institute for Cancer Research ,  Cleveland Clinic Foundation

发明人： Luc Morris ,  Timothy Chan ,  Diego Chowell ,  Cristina Valero ,  Nils Weinhold ,  Seong-Keun Yoo

IPC分类号： G16B40/20 ,  G16B20/00 ,  G16H20/17 ,  G16H50/70

CPC分类号： G16B40/20 ,  G16B20/00 ,  G16H20/17 ,  G16H50/70

摘要： The present disclosure relates generally to methods, devices, and systems for accurately predicting the efficacy of immune checkpoint blockade therapy across multiple cancer types.

公开(公告)号：US20240242816A1

公开(公告)日：2024-07-18

申请号：US18558708

申请日：2022-05-02

申请人： Memorial Sloan-Kettering Cancer Center ,  Sloan-Kettering Institute for Cancer Research ,  Memorial Hospital for Cancer and Allied Diseases

发明人： Luke Geneslaw ,  Thomas Fuchs ,  Dig Vijay Kumar Yarlagadda

IPC分类号： G16H30/20 ,  G06T7/00 ,  G06V10/20 ,  G06V10/56

CPC分类号： G16H30/20 ,  G06T7/0012 ,  G06V10/255 ,  G06V10/56 ,  G06V2201/03 ,  G06V2201/10

摘要： Presented herein are systems and methods for detecting labels in biomedical images. A computing system having one or more processors coupled with memory may identify, from a data source, a biomedical image having a first plurality of pixels in a first color representation. The computing system may convert the first plurality of pixels from the first color representation to a second color representation to generate a second plurality of pixels. The computing system may identify, from the second plurality of pixels, a subset of pixels having a color value satisfying a threshold value. The computing system may detect the biomedical image as having at least one label based at least on a number of pixels in the subset of pixels satisfying a threshold count. The computing system may store, in one or more data structures, an indication for the biomedical image as having the at least one label.

公开(公告)号：US20240216557A1

公开(公告)日：2024-07-04

申请号：US18589649

申请日：2024-02-28

申请人： Memorial Sloan-Kettering Cancer Center ,  Sloan-Kettering Institute for Cancer Research ,  Memorial Hospital for Cancer and Allied Diseases ,  Tri-Institutional Therapeutics Discovery Institute, Inc.

发明人： John T. POIRIER ,  Charles Rudin ,  Jason Lewis ,  Abdul Khan ,  David Andrew ,  Xinlei Chen ,  Ivo C. Lorenz ,  Kathryn M. Tully ,  Salomon Tendler

IPC分类号： A61K51/10

CPC分类号： A61K51/1096 ,  A61K51/1018

摘要： The presently disclosed subject matter provides compositions and methods for in vivo diagnosis and treatment of diseases or disorders associated with DLL3. In particular, the presently disclosed subject matter provides novel anti-DLL3 antibodies-TCO conjugates, which can form a radioimmunoconjugate with a radioligand comprising a radioactive isotope.

公开(公告)号：US20240189426A1

公开(公告)日：2024-06-13

申请号：US18588764

申请日：2024-02-27

申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER ,  SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES

发明人： Parwiz ABRAHIMI ,  Nan CHEN ,  Renier J. BRENTJENS ,  Jedd D. WOLCHOK ,  Taha MERGHOUB

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C12N5/0783

CPC分类号： A61K39/46447 ,  A61K39/4611 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/7151 ,  C12N5/0636 ,  C07K2319/03 ,  C12N2510/00

摘要： The presently disclosed subject matter provides for chimeric receptors that target MUC16 and cells comprising such chimeric receptors. The presently disclosed subject matter further provides uses of the chimeric receptors for treatment.

公开(公告)号：US20240189358A1

公开(公告)日：2024-06-13

申请号：US18555243

申请日：2022-04-12

申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER ,  MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES ,  SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

发明人： Scott W. Lowe ,  Corina Amor Vegas ,  Paul Romesser

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K39/00 ,  A61K45/06 ,  A61P21/00 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  A61K45/06 ,  A61P21/00 ,  C07K16/2896 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/31 ,  A61K2239/46

摘要： The present disclosure provides methods for treating Covid-related lung fibrosis or rectal cancer in a subject. Also disclosed herein are methods for delaying or mitigating the effects of aging in a subject in need thereof. The methods of the present technology comprise administering to the subject an effective amount of engineered immune cells that express a uPAR-specific chimeric antigen receptor.

公开(公告)号：US20240158487A1

公开(公告)日：2024-05-16

申请号：US18550933

申请日：2022-03-15

申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER ,  BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY ,  MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES ,  SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

发明人： Richard Kolesnick ,  Julia Busik

IPC分类号： C07K16/18 ,  A61K39/00 ,  A61P17/02

CPC分类号： C07K16/18 ,  A61P17/02 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622

摘要： The present disclosure provides compositions and methods to improve or accelerate the healing of a wound. In various embodiments, the methods comprise the use of anti-ceramide antibodies and antibody fragments. In some embodiments, the wound is a chronic wound. In some embodiments, the wound is a diabetic wound.